Therefore, we proposed that the CCT6A gene may serve as a key target in LUAD by modulating pathways such as PI-3K/AKT/mTOR, thereby affecting immune cell infiltration in the tumor microenvironment (TME) and playing a critical role in NSCLC progression and drug resistance [62]. This evidence concerns the gene AKT1 and neoplasm.